Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomised, Double-Blind, Active Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients With Heart Failure and Chronic Kidney Disease

NCT04595370 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04595370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04595370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomised, Double-Blind, Active Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients With Heart Failure and Chronic Kidney Disease
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
January 26, 2021
Completion date
September 22, 2023
Enrollment
153 (actual)
Sites
156

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, heart failure